Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 168,149 | 57,972 | N/A | N/A | N/A |
| Receivables | 20 | 36 | N/A | N/A | N/A |
| TOTAL | $170,655 | $58,030 | $N/A | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 548 | 154 | N/A | N/A | N/A |
| Other Non-Current Assets | 769 | 132 | 0 | 0 | 0 |
| TOTAL | $1,317 | $286 | $N/A | $N/A | $N/A |
| Total Assets | $171,972 | $58,316 | $N/A | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,347 | 520 | 0 | 0 | 0 |
| TOTAL | $5,387 | $819 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 605 | 100 | 0 | 0 | 0 |
| TOTAL | $605 | $100 | $N/A | $N/A | $N/A |
| Total Liabilities | $5,992 | $919 | $N/A | $N/A | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 20,503 | N/A | N/A | N/A | N/A |
| Common Shares | 4 | 2 | N/A | N/A | N/A |
| Retained earnings | -32,845 | -6,034 | N/A | N/A | N/A |
| TOTAL | $165,980 | $57,397 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $171,972 | $58,316 | $0 | $0 | $0 |